ProQR Therapeutics (NASDAQ:PRQR) Announces Quarterly Earnings Results

ProQR Therapeutics (NASDAQ:PRQR) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01), FiscalAI reports. The company had revenue of $5.50 million during the quarter, compared to analyst estimates of $6.12 million. ProQR Therapeutics had a negative return on equity of 61.64% and a negative net margin of 255.83%.

ProQR Therapeutics Stock Performance

ProQR Therapeutics stock traded up $0.10 during trading on Friday, hitting $1.82. The company’s stock had a trading volume of 524,510 shares, compared to its average volume of 285,795. The stock’s fifty day moving average is $1.64 and its 200 day moving average is $2.07. ProQR Therapeutics has a 1-year low of $1.07 and a 1-year high of $3.10. The stock has a market capitalization of $191.48 million, a price-to-earnings ratio of -3.96 and a beta of 0.21.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Osaic Holdings Inc. lifted its position in ProQR Therapeutics by 59.6% during the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 4,500 shares in the last quarter. Guggenheim Capital LLC purchased a new position in shares of ProQR Therapeutics in the 4th quarter valued at $35,000. Invesco Ltd. acquired a new position in shares of ProQR Therapeutics during the 4th quarter valued at $51,000. Simplex Trading LLC lifted its holdings in shares of ProQR Therapeutics by 44,169.0% during the 4th quarter. Simplex Trading LLC now owns 44,269 shares of the biopharmaceutical company’s stock valued at $89,000 after acquiring an additional 44,169 shares in the last quarter. Finally, Persistent Asset Partners Ltd boosted its position in ProQR Therapeutics by 24.5% during the 4th quarter. Persistent Asset Partners Ltd now owns 45,154 shares of the biopharmaceutical company’s stock worth $91,000 after purchasing an additional 8,874 shares during the period. Institutional investors and hedge funds own 32.65% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on PRQR shares. Citigroup reissued a “market outperform” rating on shares of ProQR Therapeutics in a research note on Friday. Wall Street Zen raised shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday. Oppenheimer began coverage on shares of ProQR Therapeutics in a research report on Thursday. They issued an “outperform” rating and a $9.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of ProQR Therapeutics in a research note on Thursday, January 22nd. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, ProQR Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $6.80.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.